PepsiCo (PEP)

PepsiCo (PEP) is facing numerous challenges as it contends with rising demand for weight loss drugs, particularly GLP-1 medications, which are impacting consumer behavior, especially among younger demographics who are increasingly conscious of health. The company's North American business appears to be weakening, evidenced by recent downgrades and a notable decline in demand, particularly when compared to rivals like Coca-Cola. Although PepsiCo reported strong numbers last quarter, the recent market rotation has seen significant price adjustments, leading some experts to view current share prices as a potential buying opportunity. Additionally, despite the struggles, PepsiCo maintains a solid Frito-Lay snack division and offers an attractive 4% dividend yield, which some analysts find appealing amid the current volatility in the consumer staples sector.